Combination cancer immunotherapy and new immunomodulatory targets

By K. Mahoney, P. Rennert, G. Freeman. Nature reviews. Drug discovery, 2015

1,207 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/7bfc4fa9e741aa5564078a5cdedb0ce75d65924e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Oncology

Citations in the corpus

CDK4/6 Inhibition Augments Anti-Tumor Immunity by Enhancing T Cell Activation (2017, background): “The digested NFATc3 and His-GB1 were separated and further purified using size exclusion chromatography (GE Healthcare Life Sciences “Superdex 75 10/300 GL”).”
Cancer immunotherapy: the beginning of the end of cancer? (2016, background): “Although some antitumor activity was observed for urelumab during a phase I trial [124], a phase II trial in patients with melanoma resulted in increased hepatotoxicity leading to therapy discontinuation [2].”
Cold Tumors: A Therapeutic Challenge for Immunotherapy (2019, background): “Antibodies-mediated targeting of NK activating receptors such as NKG2D and NKP46, or inhibitory receptors such as KIR and NKG2a, is under deep investigation (58).”
PD-L1 (B7-H1) and PD-1 Pathway Blockade for Cancer Therapy: Mechanisms, Response Biomarkers and Combinations (2016, background): “Additional potential combinatory strategies have been discussed in the literature (111).”
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome (2017, background): “These cytokines result in PD-L1 expression in the tissue, activating the PD-1 protein on the T cell leading to immune tolerance, a phenomenon where the immune system lose the control to mount an inflammatory response, even in the presence of actionable antigens (Mahoney et al., 2015).”
Mechanisms of resistance to immune checkpoint inhibitors (2018, background): “Additional research efforts are underway to identify biomarkers associated with resistance and response to ICI, in parallel with early phase clinical testing of novel immune modulatory agents and novel combinations of immune modulators and ICI with other cancer therapies (Mahoney et al, 2015).”
The Principles of Engineering Immune Cells to Treat Cancer (2017, background): “There are many checkpoint molecules that are induced on activated T cells that limit their effector functions (Mahoney et al., 2015), and genetic editing tools permit the efficient disruption of these molecules (Ren et al.”